Treating diabetes with autologous cell therapy: an interview with Orgenesis

In this exclusive interview, Vered Caplan, President, Chief Executive Officer and Director, and Professor Sarah Ferber, Chief Scientific Officer, Orgenesis, discuss the development of an autologous cell therapy for the treatment of insulin-resistant diabetes. Orgenesis is a biopharmaceutical company with experience in cell therapy development and manufacturing. In this video, filmed exclusively at  the Alliance for Regenerative Medicine's EU Investor Day, learn more about the challenges of developing patient-derived cell therapies.

Spotlight

Tocagen Inc.

Tocagen’s mission is to become a leading biopharmaceutical company for the treatment of cancer using cancer-selective gene therapy products based on our retroviral gene therapy platforms to increase lifespan, initially for patients with advanced local and metastatic cancer.

OTHER VIDEOS

Image analysis software for true ultra high content data on the MACSima™ Imaging System

video | July 28, 2023

Qi Tissue Image Analysis Software for the MACSima™ Imaging Platform is the key to unlocking staggering analytical ability with ultra high content imaging data generated on the revolutionary new MACSima Imaging Platform....

Watch Now

Bioprinting Living Cells: The Next Frontier in Biotechnology Technology

video | July 30, 2023

Bioprinting with living human cells is transforming healthcare as we know it. From Slurpee-like substances to molding 3D tissues, explore the cutting-edge world of 3D bioprinting. Dr. Mark Skylar-Scott from Stanford University discusses the fascinating realm of 3D bioprinting, a groundbreaking approach that goes beyond traditional plastic printing....

Watch Now

VIA Thaw™ automated dry thawer

video | May 9, 2023

VIA Thaw™ dry automated thawers give you the confidence to reliably recover cryopreserved cellular products. VIA Thaw™ L1000 intended for research or manufacturing use only is an automated dry thawer that you can use for controlled, consistent thawing of cellular products in cryobags....

Watch Now

NeatCell C-Pro application software for the Sepax™ C-Pro instrument

video | May 9, 2023

Meet the NeatCell C-Pro application. It automates the mononuclear cell fraction enrichment from diverse cellular products, and is designed for use with a density-gradient medium like Ficoll-Paque media with the Sepax C-Pro instrument and CT-90.1 single-use kit....

Watch Now

Spotlight

Tocagen Inc.

Tocagen’s mission is to become a leading biopharmaceutical company for the treatment of cancer using cancer-selective gene therapy products based on our retroviral gene therapy platforms to increase lifespan, initially for patients with advanced local and metastatic cancer.

Events